| Literature DB >> 35170080 |
Ju Jia1, Wei Shi1, Fang Dong2, Qingying Meng2, Lin Yuan1, Changhui Chen3, Kaihu Yao1.
Abstract
BACKGROUND: Some streptococci strains identified as Streptococcus pneumoniae (S. pneumoniae) by routine clinical methods exhibiting negative Quellung reaction results may belong to other species of viridans group streptococci or non-typeable S. pneumoniae. The purpose of this study was to investigate the identification and molecular characteristics of S. pneumoniae with negative Quellung reaction results.Entities:
Keywords: zzm321990Streptococcus pneumoniaezzm321990; MLSA; MLST; antimicrobial susceptibility; identification
Mesh:
Substances:
Year: 2022 PMID: 35170080 PMCID: PMC8993597 DOI: 10.1002/jcla.24293
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 2.352
FIGURE 1Genetic relationships of the 105 isolates determined by multilocus sequence analysis (MLSA). The symbols indicate the following: ● isolates obtained in this study; Streptococcus pneumoniae strains from the MLSA database; S. pseudopneumoniae strains from the MLSA database
FIGURE 2Phylogenetic tree of 105 isolates in this study with Streptococcus pneumoniae and S. pseudopneumoniae strains from the multilocus sequence analysis (MLSA) database. ■ S. pneumoniae isolates that were wrongly identified as S. pseudopneumoniae by Vitek MS. ▲ S. pseudopneumoniae isolates that were wrongly identified as S. pneumoniae by Vitek MS. ◆ S. pseudopneumoniae isolates that were wrongly identified as S. mitis/S. oralis by Vitek MS
Results of the bile solubility test and Vitek MS in this study
| Species | Bile solubility test | Vitek MS | |||
|---|---|---|---|---|---|
| Positive | Negative |
|
|
| |
|
| 81 | 0 | 75 | 6 | 0 |
|
| 5 | 19 | 6 | 15 | 3 |
FIGURE 3Population snapshot of the eBURST analysis for 81 Streptococcus pneumoniae isolates. The numbers in parentheses were the corresponding quantities of isolates for different sequence types (STs). STs without parentheses were linked to only one isolate
Non‐susceptibility rates and MIC distribution of the Streptococcus pneumoniae and Streptococcus pseudopneumoniae isolates for 14 antimicrobials
| Antibiotics |
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Non‐susceptibility | MIC (μg/ml) | Non‐susceptibility | MIC (μg/ml) | |||||||
| I% | R% | MIC50 | MIC90 | Range | I% | R% | MIC50 | MIC90 | Range | |
| Penicillin | ||||||||||
| Oral | 56.8 | 13.6 | 0.25 | 2 | ≤0.03–>4 | 54.2 | 16.6 | 0.5 | 2 | ≤0.03–>4 |
| Meningitis‐parenteral | ‐ | 70.4 | 0.25 | 2 | ≤0.03–>4 | ‐ | 70.8 | 0.5 | 2 | ≤0.03–>4 |
| Nonmeningitis‐parenteral | 3.7 | 3.7 | 0.25 | 2 | ≤0.03–>4 | 4.2 | 4.2 | 0.5 | 2 | ≤0.03–>4 |
| Amoxicillin/clavulanic acid | 3.7 | 4.9 | ≤2 | ≤2 | ≤2–16 | 4.2 | 4.2 | ≤2 | ≤2 | ≤2–8 |
| Ceftriaxone | ||||||||||
| Meningitis | 7.4 | 9.9 | ≤0.12 | 1 | ≤0.12–>2 | 8.4 | 8.4 | 0.25 | 1 | ≤0.12–>2 |
| Nonmeningitis | 3.7 | 6.2 | ≤0.12 | 1 | ≤0.12–>2 | 0 | 8.4 | 0.25 | 1 | ≤0.12–>2 |
| Cefotaxime | ||||||||||
| Meningitis | 4.9 | 6.2 | ≤0.12 | 1 | ≤0.12–>4 | 8.4 | 8.4 | 0.25 | 1 | ≤0.12–>4 |
| Nonmeningitis | 2.5 | 3.7 | ≤0.12 | 1 | ≤0.12–>4 | 0 | 8.4 | 0.25 | 1 | ≤0.12–>4 |
| Cefuroxime (parenteral) | 8.6 | 19.8 | ≤0.5 | ≥4 | ≤0.5–>4 | 8.4 | 50 | 1 | 4 | ≤0.5–>4 |
| Meropenem | 9.9 | 7.4 | ≤0.25 | 0.5 | ≤0.25–2 | 20.8 | 8.4 | ≤0.25 | 0.5 | ≤0.25–2 |
| Erythromycin | 3.7 | 74.1 | >2 | >2 | ≤0.25–>2 | 0 | 95.8 | >2 | >2 | ≤0.25–>2 |
| Azithromycin | 8.6 | 66.7 | >2 | >2 | ≤0.25–>2 | 0 | 95.8 | >2 | >2 | ≤0.25–>2 |
| Chloramphenicol | ‐ | 39.5 | 2 | 16 | ≤1–16 | ‐ | 4.2 | 2 | 4 | ≤1–8 |
| Trimethoprim/sulfamethoxazole | 44.4 | 28.4 | 2 | 4 | ≤0.5–>4 | 8.4 | 70.8 | >4 | >4 | ≤0.5–>4 |
| Tetracycline | 4.9 | 82.8 | >8 | >8 | ≤1–>8 | 0 | 91.6 | >8 | >8 | ≤1–>8 |
| Vancomycin | ‐ | ‐ | ≤0.5 | ≤0.5 | ≤0.5 | ‐ | ‐ | ≤0.5 | ≤0.5 | ≤0.5 |
| Levofloxacin | 0 | 0 | ≤0.5 | 1 | ≤0.5–1 | 0 | 0 | 1 | 1.5 | ≤0.5–2 |
| Moxifloxacin | 0 | 0 | ≤1 | ≤1 | ≤1 | 0 | 0 | ≤1 | ≤1 | ≤1 |
Abbreviation: MIC, minimum inhibitory concentration.
No breakpoints listed.